Literature DB >> 23006501

Prospective relationship of duration of untreated psychosis to psychopathology and functional outcome over 12 years.

Michele Hill1, Niall Crumlish, Mary Clarke, Peter Whitty, Elizabeth Owens, Laoise Renwick, Stephen Browne, Eric A Macklin, Anthony Kinsella, Conall Larkin, John L Waddington, Eadbhard O'Callaghan.   

Abstract

BACKGROUND: The duration of untreated psychosis is well recognised as an independent predictor of symptomatic and functional outcome in the short term and has facilitated the development of worldwide early intervention programmes. However, the extent and mechanisms by which it might influence prognosis beyond a decade remain poorly understood.
METHODS: The authors examined the relationship between duration of untreated psychosis and outcome 12years after a first episode of psychosis and assessed whether its relationship with function is affected by symptoms in a prospective, 12-year follow-up of an epidemiologically-based inception cohort.
RESULTS: Longer duration of untreated psychosis predicted poorer remission status, more severe positive and negative symptoms, and greater impairment in general functioning, social functioning and quality of life at 12years on standardised measures, independent of other factors at baseline. It was not associated with gainful employment, for which education was the only predictor, or independent living, for which age was the only predictor. The relationship between duration of untreated psychosis and functional outcome was mediated by concurrent psychopathology, particularly negative symptoms.
CONCLUSIONS: These results provide qualified support for the potential long-term benefit of reduction in the duration of untreated psychosis in terms of improvement in symptoms and functional outcome. Its failure to predict real-life outcomes such as independent living and gainful employment could reflect the importance of pre-existing socio-cultural factors such as individual opportunity. The relationship between duration of untreated psychosis and negative symptoms was largely responsible for its effect on function, suggesting a possible long-term protective mechanism against disability.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23006501     DOI: 10.1016/j.schres.2012.08.013

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  20 in total

1.  Untreated illness and recovery in clients of an early psychosis intervention program: a 10-year prospective cohort study.

Authors:  Gina Bhullar; Ross M G Norman; Neil Klar; Kelly K Anderson
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2017-11-29       Impact factor: 4.328

2.  Factor analysis of the Scale of Prodromal Symptoms: data from the Early Detection and Intervention for the Prevention of Psychosis Program.

Authors:  Ivy F Tso; Stephan F Taylor; Tyler B Grove; Tara Niendam; Steven Adelsheim; Andrea Auther; Barbara Cornblatt; Cameron S Carter; Roderick Calkins; J Daniel Ragland; Tamara Sale; William R McFarlane
Journal:  Early Interv Psychiatry       Date:  2014-12-21       Impact factor: 2.732

Review 3.  What does schizophrenia teach us about antipsychotics?

Authors:  Gary Remington; Ofer Agid; George Foussias; Gagan Fervaha; Hiroyoshi Takeuchi; Jimmy Lee; Margaret Hahn
Journal:  Can J Psychiatry       Date:  2015-03       Impact factor: 4.356

4.  Peripubertal diazepam administration prevents the emergence of dopamine system hyperresponsivity in the MAM developmental disruption model of schizophrenia.

Authors:  Yijuan Du; Anthony A Grace
Journal:  Neuropsychopharmacology       Date:  2013-04-23       Impact factor: 7.853

5.  Acceptability of Psychosis Screening and Factors Affecting Its Implementation: Interviews With Community Health Care Providers.

Authors:  Mark Savill; Haley V Skymba; J Daniel Ragland; Tara Niendam; Rachel L Loewy; Tyler A Lesh; Cameron Carter; Howard H Goldman
Journal:  Psychiatr Serv       Date:  2018-04-02       Impact factor: 3.084

6.  The 4th Schizophrenia International Research Society Conference, 5-9 April 2014, Florence, Italy: a summary of topics and trends.

Authors:  Olukayode Abayomi; Davide Amato; Candace Bailey; Byron Bitanihirwe; Lynneice Bowen; Shimon Burshtein; Alexis Cullen; Montserrat Fusté; Ana P Herrmann; Babak Khodaie; Sanja Kilian; Qortni A Lang; Elizabeth E Manning; Raffael Massuda; Milawaty Nurjono; Sarosh Sadiq; Teresa Sanchez-Gutierrez; Tamara Sheinbaum; Venkataram Shivakumar; Nicholas Simon; Anneliese Spiteri-Staines; Suttajit Sirijit; Nanna Gilliam Toftdahl; Sunali Wadehra; Yi Wang; Rebekah Wigton; Susan Wright; Sergey Yagoda; Yuliya Zaytseva; Anne O'Shea; Lynn E DeLisi
Journal:  Schizophr Res       Date:  2014-10-11       Impact factor: 4.939

7.  Associations of independent living and labor force participation with impairment indicators in schizophrenia and bipolar disorder at 20-year follow-up.

Authors:  M Strassnig; R Kotov; L Fochtmann; M Kalin; E J Bromet; P D Harvey
Journal:  Schizophr Res       Date:  2018-02-19       Impact factor: 4.939

8.  Reappraising the long-term course and outcome of psychotic disorders: the AESOP-10 study.

Authors:  C Morgan; J Lappin; M Heslin; K Donoghue; B Lomas; U Reininghaus; A Onyejiaka; T Croudace; P B Jones; R M Murray; P Fearon; G A Doody; P Dazzan
Journal:  Psychol Med       Date:  2014-02-26       Impact factor: 7.723

9.  The Psychosis Recent Onset GRoningen Survey (PROGR-S): defining dimensions and improving outcomes in early psychosis.

Authors:  Edith J Liemburg; Stynke Castelein; Frank van Es; Anne Neeltje Scholte-Stalenhoef; Gerard van de Willige; Henderikus Smid; Ellen Visser; Henderikus Knegtering; Richard Bruggeman
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

10.  Substance use and duration of untreated psychosis in KwaZulu-Natal, South Africa.

Authors:  Glen P Davis; Andrew Tomita; Joy Noel Baumgartner; Sisanda Mtshemla; Siphumelele Nene; Howard King; Ezra Susser; Jonathan K Burns
Journal:  S Afr J Psychiatr       Date:  2016-05-20       Impact factor: 1.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.